American Journal of Cardiology
Volume 106, Issue 6 , Pages 757-763 , 15 September 2010

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

  • Vincent J. Carey, PhD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: (617) 525-2265; fax: (617) 731-1541
    • ,
  • Louise Bishop, BS

      Affiliations

    • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts
    • ,
  • Nancy Laranjo, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Benjamin J. Harshfield, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Carolyn Kwiat, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Frank M. Sacks, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts

Received 26 February 2010 ,Accepted 6 May 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by the Residual Risk Reduction Initiative (R3I) Foundation (available at www.r3i.org). This Foundation has been a recipient of financial sponsorship solely from Solvay Pharmaceuticals (Abbott, Abbott Park, Illinois), although additional sponsors are actively sought. We have developed the methods and content for this research project and report with complete academic independence from the corporate sponsor of the Foundation.

PII: S0002-9149(10)01033-7

doi: 10.1016/j.amjcard.2010.05.002

American Journal of Cardiology
Volume 106, Issue 6 , Pages 757-763 , 15 September 2010

Article Tools

* Image Usage & Resolution